Calithera Biosciences, Inc.
CALA · OTC
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.00 | 0.01 |
| FCF Yield | -54.32% | -54.09% | -81.13% | -50.50% |
| EV / EBITDA | 1.09 | 1.87 | 2.23 | 0.75 |
| Quality | ||||
| ROIC | -32.20% | -32.47% | 33.60% | -34.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.24 | 0.79 | 1.24 | 1.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 1,889,781.57% | 2,136,229.34% |
| Free Cash Flow Growth | -11.44% | 31.99% | 28.96% | 37.49% |
| Safety | ||||
| Net Debt / EBITDA | 3.27 | 3.39 | 3.47 | 3.05 |
| Interest Coverage | 0.00 | 0.00 | -167.29 | -1,536.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -184.54 | 0.00 | 0.00 | 0.00 |